{
  "meta": {
    "title": "45_Respiratory_System",
    "url": "https://brainandscalpel.vercel.app/45-respiratory-system-acb17ac8.html",
    "scrapedAt": "2025-11-30T07:00:00.808Z"
  },
  "questions": [
    {
      "id": 81195,
      "choices": [
        {
          "id": 246051,
          "text": "Humanized monoclonal antibody of the IgG subclass"
        },
        {
          "id": 246052,
          "text": "It doesn’t block binding of IgE to low-affinity IgE receptors (FceRIL, CD23) on other inflammatory cells)"
        },
        {
          "id": 246053,
          "text": "Delivered as a single SC injection every 2 to 4 weeks"
        },
        {
          "id": 246054,
          "text": "Binds tightly to free IgE in the circulation to form Omalizumab-IgE"
        }
      ],
      "text": "All are true statements about Omalizumab except",
      "unique_key": "Q9377618",
      "question_audio": null,
      "question_video": null,
      "map_id": 34661726,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) It doesn’t block binding of IgE to low-affinity IgE receptors (FcεRII, CD23) on other inflammatory cells. Omalizumab is a recombinant humanized monoclonal antibody that selectively binds to free IgE in circulation. By doing so, it prevents IgE from interacting with high-affinity IgE receptors (FcεRI) on mast cells and basophils, which is crucial in allergic responses. Additionally, as the levels of free IgE decrease, the expression of FcεRI on mast cells and basophils is downregulated, reducing the allergic inflammatory response. However, Omalizumab also indirectly affects the low-affinity IgE receptors (FcεRII, CD23) present on B cells and other immune cells by lowering free IgE levels. The given statement in option B is incorrect because Omalizumab does influence CD23-mediated processes, even if its primary mechanism involves FcεRI inhibition. Explanation of the Correct Options: (A) Humanized monoclonal antibody of the IgG1 subclass This statement is correct. Omalizumab is a humanized monoclonal antibody of the IgG1 subclass, specifically designed to bind to the Cε3 domain of human IgE, preventing its interaction with FcεRI. This mechanism helps reduce allergic inflammation and symptoms in patients with conditions such as allergic asthma and chronic spontaneous urticaria. (C) Delivered as a single SC injection every 2 to 4 weeks This is correct. Omalizumab is administered subcutaneously (SC) every 2 to 4 weeks, depending on the patient's weight and baseline IgE levels. This dosing regimen ensures sustained reduction of free IgE and downregulation of FcεRI expression, thereby maintaining its therapeutic effect. (D) Binds tightly to free IgE in the circulation to form Omalizumab-IgE This is correct. Omalizumab binds with high affinity to free IgE, forming Omalizumab-IgE complexes, which prevents IgE from binding to its receptors. This action disrupts the allergic cascade by preventing mast cell degranulation and the subsequent release of inflammatory mediators.",
      "correct_choice_id": 246052,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29817441700124253/29817441700124253.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/29817441700124253/29817441700124253.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81196,
      "choices": [
        {
          "id": 246055,
          "text": "Activated by the esterases in the lung"
        },
        {
          "id": 246056,
          "text": "It has high pulmonary deposition, prolonged pulmonary residence time"
        },
        {
          "id": 246057,
          "text": "Administered through a hydrofluoroalkane propellant metered dose inhaler"
        },
        {
          "id": 246058,
          "text": "Ciclesonide and des-Ciclesonide are least bound to plasma proteins"
        }
      ],
      "text": "The following statements are true about ciclesonide except",
      "unique_key": "Q8094568",
      "question_audio": null,
      "question_video": null,
      "map_id": 34618802,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Ciclesonide and des-Ciclesonide are least bound to plasma proteins. Ciclesonide is a prodrug that is converted into its active metabolite, des-Ciclesonide, in the lungs. Both ciclesonide and its active metabolite are highly bound to plasma proteins, primarily albumin. The plasma protein binding of des-Ciclesonide is approximately 99%, meaning that only a very small fraction remains free in circulation. This high protein binding contributes to its lower systemic bioavailability, reducing the risk of systemic corticosteroid-related side effects. Since the given statement suggests that ciclesonide and des-Ciclesonide are least bound to plasma proteins, which is incorrect, option D is the correct answer. Explanation of the Correct Options: (A) Activated by the esterases in the lung This statement is correct. Ciclesonide is an inactive corticosteroid that undergoes enzymatic activation in the lungs by intracellular esterases, converting it into des-Ciclesonide, which has potent anti-inflammatory effects. This lung-specific activation helps minimize systemic corticosteroid exposure and side effects. (B) It has high pulmonary deposition, prolonged pulmonary residence time This is correct. Ciclesonide is designed to have high pulmonary deposition due to its small particle size, allowing for deeper lung penetration. Additionally, it forms lipid conjugates in lung tissues, which contributes to prolonged pulmonary residence time and sustained local anti-inflammatory effects. These properties help in maintaining its efficacy with once-daily dosing while reducing systemic side effects. (C) Administered through a hydrofluoroalkaline propellant metered dose inhaler This is correct. Ciclesonide is delivered using a hydrofluoroalkane (HFA) propellant-based metered dose inhaler (MDI). HFA propellants are environmentally friendly and help ensure efficient lung deposition of the drug compared to older chlorofluorocarbon (CFC)-based inhalers.",
      "correct_choice_id": 246058,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55720731700124267/55720731700124267.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55720731700124267/55720731700124267.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81197,
      "choices": [
        {
          "id": 246059,
          "text": "Optimal respirable particle range is between 1-5 microns"
        },
        {
          "id": 246060,
          "text": "Chlorofluorocarbons (CFC) have higher output of aerosol particles compared to hydrofluoroalkane (HFA)"
        },
        {
          "id": 246061,
          "text": "Higher particle size results in deposition in upper airways"
        },
        {
          "id": 246062,
          "text": "Smaller particles size will result in expelling out of drug during exhalation"
        }
      ],
      "text": "Which of the following is incorrect about inhaled corticosteroids",
      "unique_key": "Q8562007",
      "question_audio": null,
      "question_video": null,
      "map_id": 34638135,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Chlorofluorocarbons (CFC) have higher output of aerosol particles compared to hydrofluoroalkane (HFA). This statement is incorrect because hydrofluoroalkane (HFA)-based inhalers actually provide better aerosolization and higher lung deposition than older chlorofluorocarbon (CFC)-based inhalers. CFC propellants were used in earlier metered-dose inhalers (MDIs) but were phased out due to their environmental impact. HFA propellants generate smaller, finer aerosol particles that improve lung deposition while reducing oropharyngeal deposition. Therefore, the claim that CFCs have a higher aerosol output compared to HFAs is incorrect. Explanation of the Correct Options: (A) Optimal respirable particle range is between 1-5 microns This is correct. The ideal particle size for effective deposition in the lungs is 1-5 microns. Particles within this range are small enough to reach the lower airways but not so small that they get exhaled before deposition. If the particles are too large (>5 microns), they tend to deposit in the oropharynx and upper airways instead of reaching the lungs. (C) Higher particle size results in deposition in upper airways This is correct. Larger particles (>5 microns) tend to deposit in the upper respiratory tract, including the mouth, throat, and trachea, rather than reaching the bronchioles or alveoli. This can lead to local side effects such as oral candidiasis (thrush) and hoarseness, which are common issues with inhaled corticosteroids if proper inhaler technique and rinsing of the mouth after use are not followed. (D) Smaller particle size will result in expelling out of drug during exhalation This is correct. If the aerosolized drug particles are too small (<1 micron), they are not effectively deposited in the lungs and may be exhaled before they can act. This reduces the drug’s efficacy and leads to wastage. Hence, maintaining an optimal particle size (1-5 microns) is essential for effective delivery.",
      "correct_choice_id": 246060,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/73420091700124278/73420091700124278.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/73420091700124278/73420091700124278.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81198,
      "choices": [
        {
          "id": 246063,
          "text": "Beclamethasone dipropionate"
        },
        {
          "id": 246064,
          "text": "Triamcinolone"
        },
        {
          "id": 246065,
          "text": "Budesonide"
        },
        {
          "id": 246066,
          "text": "All of the above"
        }
      ],
      "text": "Preferred ICS in patients of asthma requiring high doses (>1000 ug) of ICS is",
      "unique_key": "Q8879578",
      "question_audio": null,
      "question_video": null,
      "map_id": 34225173,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Budesonide. Budesonide is the preferred inhaled corticosteroid (ICS) for patients requiring high doses (>1000 µg/day) because of its favorable efficacy-to-safety profile, high lung deposition, and lower systemic absorption compared to other ICSs. It has a high glucocorticoid receptor affinity, leading to potent anti-inflammatory effects with relatively lower systemic bioavailability. Budesonide is also rapidly metabolized by the liver (via first-pass metabolism), reducing systemic side effects, making it a safer option for long-term high-dose use. It is commonly used in moderate to severe asthma where high-dose ICS therapy is required. Explanation of the Incorrect Options: (A) Beclomethasone dipropionate This is incorrect because although beclomethasone dipropionate is an effective ICS, it has lower pulmonary deposition and a higher risk of systemic side effects when used in high doses compared to budesonide. Its conversion into the active metabolite (17-beclomethasone monopropionate) also contributes to variability in its potency, making it less preferred for high-dose ICS therapy. (B) Triamcinolone Triamcinolone is not commonly used as an ICS in asthma management due to its lower potency and higher systemic absorption, which increases the risk of systemic corticosteroid side effects such as adrenal suppression and osteoporosis. It is less effective at reducing airway inflammation compared to budesonide, making it a non-preferred choice for high-dose ICS therapy. (D) All of the above This is incorrect because not all ICSs listed are preferred in patients requiring high doses. Budesonide stands out as the most suitable option due to its high efficacy, lung deposition, and safety profile. Beclomethasone and triamcinolone are not as effective or safe in high doses.",
      "correct_choice_id": 246065,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/15537981700124295/15537981700124295.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/15537981700124295/15537981700124295.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81199,
      "choices": [
        {
          "id": 246067,
          "text": "Deactivation histone deacetylase"
        },
        {
          "id": 246068,
          "text": "PDE 4 inhibition"
        },
        {
          "id": 246069,
          "text": "Blockade of adenosine receptors"
        },
        {
          "id": 246070,
          "text": "Interleukin-10 release"
        }
      ],
      "text": "The following are mechanism of Methylxanthines in bronchial asthma and COPD except",
      "unique_key": "Q2581358",
      "question_audio": null,
      "question_video": null,
      "map_id": 34020937,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Deactivation of histone deacetylase. Methylxanthines, such as theophylline, have multiple mechanisms of action in bronchial asthma and chronic obstructive pulmonary disease (COPD), but they do not deactivate histone deacetylase (HDAC). In fact, they are known to enhance HDAC activity, which plays a role in reducing inflammation. HDAC activation helps suppress pro-inflammatory gene transcription, making it a beneficial mechanism in corticosteroid-resistant asthma and COPD. Since the statement suggests that methylxanthines deactivate HDAC (which is incorrect), option A is the correct answer. Explanation of the Correct Options: (B) PDE4 inhibition This statement is correct. Methylxanthines, particularly theophylline, inhibit phosphodiesterase (PDE) enzymes, especially PDE4 in inflammatory cells. PDE4 inhibition increases cyclic AMP (cAMP) levels, leading to bronchodilation and anti-inflammatory effects. This is particularly important in COPD, where PDE4 inhibition helps reduce airway inflammation. (C) Blockade of adenosine receptors This is correct. Methylxanthines antagonize adenosine receptors (A1 and A2A), which contributes to their bronchodilator effects. Adenosine normally promotes bronchoconstriction and inflammation by stimulating mast cells to release histamine. By blocking adenosine receptors, methylxanthines reduce bronchospasm and airway hyperresponsiveness in asthma and COPD. (D) Interleukin-10 release This is correct. Methylxanthines have been shown to increase interleukin-10 (IL-10) levels, which is important because IL-10 is an anti-inflammatory cytokine. Increased IL-10 production helps suppress excessive inflammation in airway diseases like asthma and COPD, contributing to their immunomodulatory effects.",
      "correct_choice_id": 246067,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/911191700124305/911191700124305.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/911191700124305/911191700124305.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81200,
      "choices": [
        {
          "id": 246071,
          "text": "Aspirin induced asthma"
        },
        {
          "id": 246072,
          "text": "Treatment of asthma"
        },
        {
          "id": 246073,
          "text": "Prophylaxis of exercise-induced bronchospasm"
        },
        {
          "id": 246074,
          "text": "COPD"
        }
      ],
      "text": "Formoterol is FDA approved for treatment of following conditions except",
      "unique_key": "Q2620942",
      "question_audio": null,
      "question_video": null,
      "map_id": 34965058,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Aspirin-induced asthma. Formoterol, a long-acting ?2-agonist (LABA), is not specifically FDA-approved for aspirin-induced asthma (AIA), also known as aspirin-exacerbated respiratory disease (AERD). AIA is characterized by bronchoconstriction, nasal polyps, and chronic rhinosinusitis triggered by nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin. While formoterol can help bronchodilate and relieve asthma symptoms, it does not target the underlying pathophysiology of AIA, which involves leukotriene overproduction. The mainstay treatment for AIA includes leukotriene receptor antagonists (e.g., montelukast), corticosteroids, and aspirin desensitization, making formoterol unsuitable as a primary therapy. Explanation of the Correct Options: (B) Treatment of asthma This statement is correct. Formoterol is FDA-approved for asthma treatment, but only in combination with an inhaled corticosteroid (ICS), such as budesonide or mometasone. Due to its long-acting nature, formoterol should not be used as monotherapy for asthma, as LABA use alone has been associated with an increased risk of asthma-related deaths. However, when combined with an ICS, formoterol provides sustained bronchodilation and helps in long-term asthma control. (C) Prophylaxis of exercise-induced bronchospasm (EIB) This is correct. Formoterol is approved for the prevention of exercise-induced bronchospasm. As a LABA with a rapid onset of action (within minutes), it provides long-lasting bronchodilation (up to 12 hours), making it effective for EIB prophylaxis. However, due to concerns about LABA monotherapy, it is recommended to be used in combination with an ICS if prescribed for regular asthma control. (D) COPD This is correct. Formoterol is FDA-approved for COPD, where it helps reduce airway resistance, improve lung function, and relieve breathlessness. It is commonly used as a maintenance bronchodilator in moderate to severe COPD, often in combination with long-acting muscarinic antagonists (LAMAs) or ICS in patients with frequent exacerbations.",
      "correct_choice_id": 246071,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/42066831700124316/42066831700124316.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/42066831700124316/42066831700124316.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81201,
      "choices": [
        {
          "id": 246075,
          "text": "Prodrug of terbutaline"
        },
        {
          "id": 246076,
          "text": "Hydrolyzed by pseudocholinestrase in lungs"
        },
        {
          "id": 246077,
          "text": "Used in chronic asthma"
        },
        {
          "id": 246078,
          "text": "It is an amide drug"
        }
      ],
      "text": "Following statements are true about bambuterol except",
      "unique_key": "Q7587277",
      "question_audio": null,
      "question_video": null,
      "map_id": 34971844,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) It is an amide drug. Bambuterol is not an amide drug, but rather a carbamate derivative of terbutaline. It is a prodrug that is gradually converted into its active form, terbutaline, through hydrolysis by plasma pseudocholinesterase. The carbamate group in bambuterol plays a crucial role in its slow activation, leading to prolonged bronchodilation with once-daily dosing. Since the given statement incorrectly classifies bambuterol as an amide drug, option D is the correct answer. Explanation of the Correct Options: (A) Prodrug of terbutaline This statement is correct. Bambuterol is a prodrug that is metabolized into terbutaline, a short-acting β2-agonist (SABA). The prodrug form allows for a slower release and longer duration of action, making bambuterol suitable for chronic asthma management rather than acute relief. (B) Hydrolyzed by pseudocholinesterase in lungs This is correct. Bambuterol is hydrolyzed by plasma pseudocholinesterase to form terbutaline. Although most of this metabolism occurs in the liver and plasma, some conversion may also take place in lung tissues. The slow hydrolysis contributes to its prolonged bronchodilatory effect, distinguishing it from terbutaline, which has a shorter duration of action. (C) Used in chronic asthma This is correct. Due to its long duration of action, bambuterol is used as a maintenance therapy for chronic asthma. It is taken orally once daily, making it a convenient alternative to inhaled bronchodilators in patients who prefer or require oral therapy. However, it is not suitable for acute asthma attacks, where fast-acting β2-agonists like salbutamol or terbutaline inhalers are preferred.",
      "correct_choice_id": 246078,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/77879411700124329/77879411700124329.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/77879411700124329/77879411700124329.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81202,
      "choices": [
        {
          "id": 246079,
          "text": "Beclamethasone dipropionate"
        },
        {
          "id": 246080,
          "text": "Fluticasone hemihydrate"
        },
        {
          "id": 246081,
          "text": "Fluticasone propionate"
        },
        {
          "id": 246082,
          "text": "Fluticasone furoate"
        }
      ],
      "text": "Which of the following inhaled corticosteroids (ICS) has long duration of action",
      "unique_key": "Q7202754",
      "question_audio": null,
      "question_video": null,
      "map_id": 34008556,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Fluticasone furoate. Among the inhaled corticosteroids (ICS), Fluticasone furoate has the longest duration of action due to its high receptor affinity and prolonged retention in lung tissues. Comparison of ICS Duration of Action: 1. Beclomethasone dipropionate → Intermediate duration 2. Fluticasone hemihydrate → Less commonly used form 3. Fluticasone propionate → Intermediate to long duration (commonly used in asthma and COPD) 4. Fluticasone furoate → Longest duration (Once-daily dosing due to high glucocorticoid receptor affinity and slow lung clearance) Why Fluticasone Furoate? It has a higher lipophilicity and stronger receptor binding than other ICS. Allows once-daily dosing, making it more convenient for patients. Used in asthma (with LABA like vilanterol) and COPD for long-term control.",
      "correct_choice_id": 246082,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/70207931700124345/70207931700124345.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/70207931700124345/70207931700124345.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81203,
      "choices": [
        {
          "id": 246083,
          "text": "Inhibiting production of IgE"
        },
        {
          "id": 246084,
          "text": "Inhibiting Cyclooxygenase"
        },
        {
          "id": 246085,
          "text": "Inhibiting Lipoxygenase"
        },
        {
          "id": 246086,
          "text": "Inhibiting mast cell degranulation"
        }
      ],
      "text": "Zileuton acts by",
      "unique_key": "Q7888467",
      "question_audio": null,
      "question_video": null,
      "map_id": 34424852,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Inhibiting Lipoxygenase. Zileuton is a 5-lipoxygenase (5-LOX) inhibitor, which prevents the conversion of arachidonic acid into leukotrienes (LTB4, LTC4, LTD4, and LTE4). Leukotrienes are key mediators of airway inflammation, bronchoconstriction, and mucus secretion in asthma. By blocking 5-lipoxygenase, zileuton reduces leukotriene production, leading to decreased bronchoconstriction, inflammation, and airway hyperresponsiveness. It is used primarily in the management of asthma, particularly in patients with aspirin-exacerbated respiratory disease (AERD), where leukotrienes play a major pathogenic role. Explanation of the Incorrect Options: (A) Inhibiting production of IgE This is incorrect because zileuton does not affect IgE production. IgE synthesis is primarily regulated by B cells and cytokines like IL-4 and IL-13. Medications like omalizumab, a monoclonal antibody against IgE, are used to reduce IgE levels in allergic asthma. Zileuton, however, acts on the lipoxygenase pathway and does not interfere with IgE production. (B) Inhibiting Cyclooxygenase (COX) This is incorrect because zileuton does not inhibit cyclooxygenase (COX-1 or COX-2). The COX pathway leads to the production of prostaglandins and thromboxanes, which are different from leukotrienes. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin and ibuprofen, inhibit COX enzymes, whereas zileuton specifically targets the lipoxygenase pathway without affecting prostaglandin synthesis. (D) Inhibiting mast cell degranulation This is incorrect because zileuton does not directly inhibit mast cell degranulation, which is responsible for the release of histamine and other mediators in allergic reactions. Mast cell stabilizers such as cromolyn sodium and nedocromil work by preventing mast cell degranulation. Zileuton primarily works by reducing leukotriene synthesis, which indirectly reduces inflammation but does not directly stabilize mast cells.",
      "correct_choice_id": 246085,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26985881700124358/26985881700124358.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/26985881700124358/26985881700124358.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81204,
      "choices": [
        {
          "id": 246087,
          "text": "A1 receptor antagonism"
        },
        {
          "id": 246088,
          "text": "Both A1 receptor antagonism and PDE 3 inhibition"
        },
        {
          "id": 246089,
          "text": "PDE 3 inhibition"
        },
        {
          "id": 246090,
          "text": "PDE 4 inhibition"
        }
      ],
      "text": "Proposed mechanism for cardiac arrhythmia caused by theophylline is due to",
      "unique_key": "Q4988667",
      "question_audio": null,
      "question_video": null,
      "map_id": 34077449,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Both A1 receptor antagonism and PDE3 inhibition. Theophylline, a methylxanthine derivative, can cause cardiac arrhythmias due to its dual mechanism of A1 adenosine receptor antagonism and phosphodiesterase-3 (PDE3) inhibition. A1 receptor antagonism: Theophylline blocks A1 adenosine receptors, which normally act to reduce heart rate and suppress excitability of cardiac pacemaker cells. By antagonizing these receptors, theophylline leads to increased heart rate (positive chronotropic effect) and enhanced conduction through the AV node, which can trigger arrhythmias. PDE3 inhibition: Theophylline inhibits PDE3, leading to an increase in cyclic AMP (cAMP) levels in cardiac myocytes. Elevated cAMP enhances calcium influx, causing increased contractility (positive inotropic effect) and heightened excitability of cardiac cells, predisposing the heart to ectopic beats and arrhythmias. Due to these combined effects on cardiac excitability, theophylline can cause supraventricular and ventricular arrhythmias, particularly at higher doses or in patients with underlying heart disease. Incorrect Options: (A) A1 receptor antagonism This is incorrect because while A1 receptor antagonism contributes to arrhythmias by increasing heart rate and excitability, it is not the sole mechanism. PDE3 inhibition also plays a crucial role in arrhythmia induction. Therefore, both mechanisms together (option B) provide a more accurate explanation. (C) PDE3 inhibition This is incorrect because PDE3 inhibition alone does not fully explain the arrhythmogenic effects of theophylline. While it increases cAMP levels and enhances cardiac contractility, the loss of A1 receptor-mediated inhibitory effects on heart rate and conduction also plays a significant role. The combination of A1 receptor antagonism and PDE3 inhibition is more likely to cause arrhythmias than PDE3 inhibition alone. (D) PDE4 inhibition This is incorrect because PDE4 inhibition is mainly involved in anti-inflammatory effects in the lungs rather than cardiac effects. Theophylline's inhibition of PDE4 contributes to bronchodilation and reduced airway inflammation, making it useful in asthma and COPD treatment. However, PDE4 inhibition is not the primary mechanism for cardiac arrhythmias, making this option incorrect.",
      "correct_choice_id": 246088,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36062361700124387/36062361700124387.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/36062361700124387/36062361700124387.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81205,
      "choices": [
        {
          "id": 246091,
          "text": "It an enantiomer of Formoterol"
        },
        {
          "id": 246092,
          "text": "It cannot be used with a nebulizer"
        },
        {
          "id": 246093,
          "text": "It has twice the potency of racemic formoterol"
        },
        {
          "id": 246094,
          "text": "It is FDA-approved for the long-term treatment of bronchoconstriction in patients with COPD"
        }
      ],
      "text": "Which of the following is incorrect about AR formoterol",
      "unique_key": "Q2635208",
      "question_audio": null,
      "question_video": null,
      "map_id": 34176809,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) It cannot be used with a nebulizer. This statement is incorrect because arformoterol is specifically formulated for nebulization. It is available as an inhalation solution and is administered via a nebulizer for long-term maintenance treatment of bronchoconstriction in patients with COPD. Unlike formoterol, which is available in dry powder inhalers (DPI) and metered-dose inhalers (MDI), arformoterol is designed for nebulized administration, making it particularly useful for patients who have difficulty using inhalers, such as those with severe COPD or limited inspiratory capacity. Explanation of the Incorrect Options: (A) It is an enantiomer of Formoterol This statement is correct. Arformoterol is the (R,R)-enantiomer of racemic formoterol, which means it is a more pharmacologically active version of formoterol. Since enantiomers can have different biological activities, arformoterol has greater β2-agonist selectivity, making it a more potent bronchodilator than the racemic mixture. (C) It has twice the potency of racemic formoterol This statement is correct. Since arformoterol is the (R,R)-enantiomer, it exhibits approximately twice the potency of the racemic formoterol mixture, meaning a lower dose of arformoterol can achieve the same bronchodilatory effect as a higher dose of formoterol. This increased potency allows for effective long-acting bronchodilation with lower drug exposure. (D) It is FDA-approved for the long-term treatment of bronchoconstriction in patients with COPD This statement is correct. The FDA has approved arformoterol for long-term maintenance treatment of COPD, including chronic bronchitis and emphysema. It is not approved for asthma treatment due to concerns regarding the safety of long-acting β2-agonists (LABAs) as monotherapy in asthma. However, in COPD, arformoterol is a valuable long-acting bronchodilator that helps improve lung function, reduce symptoms, and enhance exercise tolerance.",
      "correct_choice_id": 246092,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55103751700124410/55103751700124410.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/55103751700124410/55103751700124410.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81206,
      "choices": [
        {
          "id": 246095,
          "text": "Cromolyn sodium"
        },
        {
          "id": 246096,
          "text": "Ipratropium bromide"
        },
        {
          "id": 246097,
          "text": "Beclamethasone"
        },
        {
          "id": 246098,
          "text": "Salbutamol"
        }
      ],
      "text": "A 55-year-old female who is taking Propanolol for the management of a cardiovascular disease experiences an acute asthmatic attack. Which of the following drugs would you prescribe to attenuate this asthmatic attack?",
      "unique_key": "Q9628668",
      "question_audio": null,
      "question_video": null,
      "map_id": 34072898,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Ipratropium bromide. Ipratropium bromide is a short-acting muscarinic antagonist (SAMA) that works by blocking muscarinic (M3) receptors in the airways, leading to bronchodilation. It is particularly useful in patients with acute asthma exacerbations who are on β-blockers like propranolol because it acts independently of the β2-adrenergic receptor pathway. Since propranolol is a non-selective β-blocker, it can block β2-receptors in the lungs, reducing the effectiveness of β2-agonists like salbutamol. Ipratropium provides bronchodilation without relying on β2-receptor activation, making it the preferred choice in this scenario. Explanation of the Incorrect Options: (A) Cromolyn sodium This is incorrect because cromolyn sodium is a mast cell stabilizer that prevents the release of inflammatory mediators like histamine and leukotrienes. However, it is not effective for acute asthma attacks since it does not directly induce bronchodilation. Cromolyn is primarily used for prophylaxis in asthma, especially in allergic asthma, but is not suitable for emergency treatment of an acute exacerbation. (C) Beclomethasone This is incorrect because beclomethasone is an inhaled corticosteroid (ICS), which helps reduce airway inflammation over time but does not provide immediate bronchodilation. ICSs are used as long-term maintenance therapy in asthma but are not effective for relieving acute symptoms. During an acute attack, a rapid bronchodilator is required, making beclomethasone an inappropriate choice. (D) Salbutamol This is incorrect because salbutamol (a short-acting β2-agonist, SABA) is normally the first-line treatment for acute asthma attacks, but in this case, the patient is taking propranolol, a non-selective β-blocker. Propranolol blocks β2-receptors in the lungs, which reduces the bronchodilatory effects of salbutamol, making it less effective or even ineffective in relieving the asthma attack. This is why ipratropium bromide, which does not rely on β2-receptors, is the preferred choice.",
      "correct_choice_id": 246096,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/53536221700124445/53536221700124445.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/53536221700124445/53536221700124445.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81207,
      "choices": [
        {
          "id": 246099,
          "text": "Formoterol"
        },
        {
          "id": 246100,
          "text": "Bambuterol"
        },
        {
          "id": 246101,
          "text": "Salmeterol"
        },
        {
          "id": 246102,
          "text": "Terbutaline"
        }
      ],
      "text": "Which of the following Beta 2 agonists is given by inhalation, and is suitable for both terminating acute asthma attacks as well as for twice daily prophylaxis?",
      "unique_key": "Q1364543",
      "question_audio": null,
      "question_video": null,
      "map_id": 34488799,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Formoterol. Formoterol is a long-acting β2-agonist (LABA) that is unique among LABAs due to its rapid onset of action (within 2–3 minutes) and prolonged duration of effect (up to 12 hours). This dual characteristic allows formoterol to be used both for terminating acute asthma attacks and for twice-daily maintenance therapy. In clinical practice, formoterol is often combined with an inhaled corticosteroid (ICS) in a single inhaler, such as budesonide/formoterol or mometasone/formoterol, to provide both immediate relief and long-term control of asthma symptoms. This combination approach is known as Single Maintenance and Reliever Therapy (SMART) and has been shown to reduce asthma exacerbations effectively. Incorrect Options: (B) Bambuterol This is incorrect because bambuterol is an oral prodrug of terbutaline, a short-acting β2-agonist. Bambuterol is administered orally and has a delayed onset of action, making it unsuitable for the rapid relief of acute asthma symptoms. It is primarily used for maintenance therapy rather than for terminating acute attacks. (C) Salmeterol This is incorrect because salmeterol is a long-acting β2-agonist with a slower onset of action (approximately 10–20 minutes) compared to formoterol. Due to its delayed onset, salmeterol is not suitable for relieving acute asthma attacks and is used exclusively for twice-daily maintenance therapy to prevent symptoms. (D) Terbutaline This is incorrect because terbutaline is a short-acting β2-agonist (SABA) with a rapid onset of action, making it effective for terminating acute asthma attacks. However, due to its short duration of action (4–6 hours), it is not suitable for twice-daily prophylaxis. Terbutaline is typically used on an as-needed basis for quick relief of symptoms.",
      "correct_choice_id": 246099,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/18820861700124456/18820861700124456.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/18820861700124456/18820861700124456.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81208,
      "choices": [
        {
          "id": 246103,
          "text": "Digitalis Toxicity"
        },
        {
          "id": 246104,
          "text": "Breast carcinoma"
        },
        {
          "id": 246105,
          "text": "Rheumatoid arthritis"
        },
        {
          "id": 246106,
          "text": "Bronchial asthma"
        }
      ],
      "text": "Omalizumab is a monoclonal antibody used for treatment of",
      "unique_key": "Q2794252",
      "question_audio": null,
      "question_video": null,
      "map_id": 34696745,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Bronchial asthma. Omalizumab is a recombinant humanized monoclonal antibody that selectively binds to human immunoglobulin E (IgE). By inhibiting IgE binding to its high-affinity receptors on mast cells and basophils, omalizumab prevents the release of inflammatory mediators associated with allergic responses. This mechanism makes it effective in treating moderate to severe persistent allergic asthma in patients aged 6 years and older whose symptoms are inadequately controlled with inhaled corticosteroids. ACCESSDATA.FDA.GOV Explanation of the Incorrect Options: (A) Digitalis Toxicity Digitalis toxicity refers to the toxic effects of cardiac glycosides like digoxin. Management typically involves discontinuing the offending agent, correcting electrolyte imbalances, and administering specific antidotes such as digoxin-specific antibody fragments (digoxin immune Fab). Omalizumab does not play a role in the treatment of digitalis toxicity. (B) Breast Carcinoma Breast carcinoma is commonly treated with a combination of surgery, chemotherapy, radiation therapy, and targeted therapies such as trastuzumab for HER2-positive cancers. Omalizumab is not indicated for the treatment of breast cancer. (C) Rheumatoid Arthritis Rheumatoid arthritis is an autoimmune disease primarily managed with disease-modifying antirheumatic drugs (DMARDs), including methotrexate, and biologic agents targeting specific immune pathways, such as tumor necrosis factor (TNF) inhibitors. Omalizumab is not approved for the treatment of rheumatoid arthritis.",
      "correct_choice_id": 246106,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/12438651700124466/12438651700124466.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/12438651700124466/12438651700124466.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81209,
      "choices": [
        {
          "id": 246107,
          "text": "Pneumonia"
        },
        {
          "id": 246108,
          "text": "Pituitary and adrenal suppression"
        },
        {
          "id": 246109,
          "text": "Atrophic rhinitis"
        },
        {
          "id": 246110,
          "text": "Oropharyngeal candidiasis"
        }
      ],
      "text": "One of the most common side effects of inhaled beclomethasone dipropionate is",
      "unique_key": "Q8231039",
      "question_audio": null,
      "question_video": null,
      "map_id": 34266210,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Oropharyngeal candidiasis. Oropharyngeal candidiasis, also known as oral thrush, is a common side effect of inhaled corticosteroids like beclomethasone dipropionate. This condition occurs when the medication deposits in the mouth and throat, leading to a fungal infection characterized by white patches, redness, and soreness. To minimize this risk, it is recommended to rinse the mouth with water and spit it out after each inhalation. Using a spacer device with the inhaler can also help reduce medication deposition in the oropharyngeal area. NHS.UK Explanation of the Incorrect Options: (A) Pneumonia While inhaled corticosteroids have been associated with an increased risk of pneumonia, particularly in patients with chronic obstructive pulmonary disease (COPD), this is less common compared to oropharyngeal candidiasis. The risk of pneumonia is generally more concerning with higher doses and prolonged use. (B) Pituitary adrenal suppression Pituitary adrenal suppression can occur with systemic absorption of corticosteroids, leading to decreased cortisol production. However, this side effect is relatively rare with inhaled forms like beclomethasone, especially when used at recommended doses. The inhaled route minimizes systemic exposure, thereby reducing the likelihood of significant adrenal suppression. (C) Atrophic rhinitis Atrophic rhinitis, characterized by chronic nasal inflammation and thinning of the nasal mucosa, is not commonly associated with inhaled beclomethasone use. This condition is more related to nasal sprays or systemic conditions rather than inhaled corticosteroids targeting the lower respiratory tract.",
      "correct_choice_id": 246110,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/47325841700124477/47325841700124477.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/47325841700124477/47325841700124477.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81210,
      "choices": [
        {
          "id": 246111,
          "text": "Produce slower response in bronchial asthma"
        },
        {
          "id": 246112,
          "text": "Are better suited for control of an acute attack of asthma"
        },
        {
          "id": 246113,
          "text": "Are more effective in bronchial asthma"
        },
        {
          "id": 246114,
          "text": "Produce little benefit in chronic-obstructive lung disease"
        }
      ],
      "text": "In comparison to inhaled adrenergic agonists, the inhaled anticholinergics?",
      "unique_key": "Q4142289",
      "question_audio": null,
      "question_video": null,
      "map_id": 34416923,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Produce slower response in bronchial asthma. Inhaled anticholinergics, such as ipratropium bromide, function by blocking muscarinic receptors in the airways, leading to bronchodilation. However, compared to inhaled adrenergic agonists (β2-agonists), they have a slower onset of action. This slower response makes them less suitable for the rapid relief of acute asthma symptoms. Therefore, the statement that inhaled anticholinergics produce a slower response in bronchial asthma is correct. Incorrect Options: (B) Are better suited for control of an acute attack of asthma This statement is incorrect. Due to their slower onset of action, inhaled anticholinergics are not typically used as the primary treatment for acute asthma attacks. Instead, short-acting β2-agonists (SABAs), such as albuterol, are preferred for rapid symptom relief. Anticholinergics may be used as adjunct therapy in certain situations but are not the first-line treatment for acute exacerbations. (C) Are more effective in bronchial asthma This statement is incorrect. Inhaled anticholinergics are generally less effective than β2-agonists in treating bronchial asthma. While they can provide bronchodilation, their slower onset and lesser efficacy make them less suitable as monotherapy for asthma. They are more commonly used in the management of chronic obstructive pulmonary disease (COPD), where cholinergic tone plays a more significant role in airway constriction. (D) Produce little benefit in chronic obstructive lung disease This statement is incorrect. Inhaled anticholinergics are actually beneficial in the management of chronic obstructive pulmonary disease (COPD). They help reduce bronchoconstriction and are often used as first-line bronchodilator therapy in COPD patients. Their efficacy in COPD is well-established, making this statement inaccurate.",
      "correct_choice_id": 246111,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/54127761700124486/54127761700124486.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/54127761700124486/54127761700124486.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81211,
      "choices": [
        {
          "id": 246115,
          "text": "Budesonide"
        },
        {
          "id": 246116,
          "text": "Ipratropium bromide"
        },
        {
          "id": 246117,
          "text": "Theophylline"
        },
        {
          "id": 246118,
          "text": "Terbutaline"
        }
      ],
      "text": "Which of the following drugs CANNOT be administered by inhalation?",
      "unique_key": "Q3131881",
      "question_audio": null,
      "question_video": null,
      "map_id": 34586556,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Theophylline. Theophylline is primarily administered via oral and intravenous routes. It is available in various oral formulations, including extended-release tablets, capsules, and solutions, as well as in an intravenous form for acute care settings. Theophylline is not formulated for inhalation therapy. Its systemic administration allows for bronchodilation and anti-inflammatory effects in the management of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Explanation of the Incorrect Options: (A) Budesonide This statement is incorrect. Budesonide is an inhaled corticosteroid (ICS) commonly used in the management of asthma and COPD. It is administered via inhalation devices such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs), delivering the medication directly to the lungs to reduce inflammation and prevent exacerbations. (B) Ipratropium bromide This statement is incorrect. Ipratropium bromide is an inhaled anticholinergic bronchodilator used to relieve bronchospasm associated with COPD and, in some cases, asthma. It is delivered through inhalation devices, including MDIs and nebulizers, providing targeted action in the airways. (D) Terbutaline This statement is incorrect. Terbutaline is a short-acting β2-agonist (SABA) that can be administered via inhalation to provide rapid bronchodilation in acute asthma attacks. It is available in inhalation forms, such as MDIs, as well as in oral and injectable formulations.",
      "correct_choice_id": 246117,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/69293851700124497/69293851700124497.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/69293851700124497/69293851700124497.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81212,
      "choices": [
        {
          "id": 246119,
          "text": "Those receiving cimetidine"
        },
        {
          "id": 246120,
          "text": "Congestive heart failure patients"
        },
        {
          "id": 246121,
          "text": "Those receiving erythromycin"
        },
        {
          "id": 246122,
          "text": "Smokers"
        }
      ],
      "text": "Relatively higher dose of theophylline is required to attain therapeutic plasma concentration in",
      "unique_key": "Q4481401",
      "question_audio": null,
      "question_video": null,
      "map_id": 34346449,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Smokers. Smokers require relatively higher doses of theophylline to attain therapeutic plasma concentrations due to increased drug metabolism. Components in cigarette smoke, particularly polycyclic aromatic hydrocarbons, induce hepatic enzymes such as cytochrome P450 1A2 (CYP1A2). This induction leads to enhanced clearance of theophylline, necessitating higher doses to achieve therapeutic effects. Studies have shown that theophylline clearance in smokers is significantly higher than in non-smokers. Explanation of the Incorrect Options: (A) Those receiving cimetidine This is incorrect because cimetidine is a known inhibitor of CYP1A2. Co-administration of cimetidine with theophylline can decrease theophylline clearance, leading to higher plasma concentrations and an increased risk of toxicity. Therefore, patients receiving cimetidine may require lower, not higher, doses of theophylline. (B) Congestive heart failure patients This is incorrect because patients with congestive heart failure (CHF) often exhibit reduced hepatic blood flow, which can decrease the clearance of theophylline. As a result, these patients are at a higher risk of elevated theophylline levels and potential toxicity, necessitating careful dosing and monitoring. (C) Those receiving erythromycin This is incorrect because erythromycin inhibits CYP3A4 and can decrease the metabolism of theophylline, leading to increased plasma concentrations. Consequently, patients taking erythromycin may require lower doses of theophylline to avoid adverse effects.",
      "correct_choice_id": 246122,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/47738351700124507/47738351700124507.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/47738351700124507/47738351700124507.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81213,
      "choices": [
        {
          "id": 246123,
          "text": "Its plasma half-life is longer in children as compared to that in adults"
        },
        {
          "id": 246124,
          "text": "Its dose needs to be reduced in the smokers"
        },
        {
          "id": 246125,
          "text": "It acts by increasing the formation of cAMP"
        },
        {
          "id": 246126,
          "text": "Its use in asthma has declined because of narrow safety margin"
        }
      ],
      "text": "Which of the following statements about theophylline is TRUE?",
      "unique_key": "Q9146390",
      "question_audio": null,
      "question_video": null,
      "map_id": 34633896,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Its use in asthma has declined because of narrow safety margin. Theophylline has historically been used to manage asthma due to its bronchodilator and anti-inflammatory properties. However, its clinical use has significantly declined because of its narrow therapeutic index, meaning the range between therapeutic and toxic plasma concentrations is small. This narrow safety margin necessitates regular monitoring of serum theophylline levels to avoid adverse effects, which can include nausea, vomiting, arrhythmias, and seizures. Consequently, safer and more effective alternatives, such as inhaled corticosteroids and long-acting ??-agonists, are now preferred in asthma management. NCBI.NLM.NIH.GOV Explanation of the Incorrect Options: (A) Its plasma half-life is longer in children as compared to that in adults This statement is incorrect. In fact, the plasma half-life of theophylline is generally shorter in children than in adults. Children metabolize theophylline more rapidly, resulting in a shorter half-life and necessitating more frequent dosing to maintain therapeutic levels. In contrast, adults, especially the elderly, may exhibit a longer half-life due to decreased metabolic clearance. ACCESSDATA.FDA.GOV (B) Its dose needs to be reduced in smokers This statement is incorrect. Smokers metabolize theophylline more rapidly due to the induction of hepatic enzymes by components in cigarette smoke, leading to increased clearance of the drug. As a result, smokers often require higher doses of theophylline to achieve therapeutic plasma concentrations, not reduced doses. Conversely, if a smoker quits smoking, theophylline clearance decreases, and dose adjustments are necessary to prevent toxicity. ACCESSDATA.FDA.GOV (C) It acts by increasing the formation of cAMP This statement is partially correct but not entirely accurate. Theophylline's primary mechanism of action involves inhibition of phosphodiesterase (PDE) enzymes, particularly PDE3 and PDE4, leading to decreased breakdown of cyclic AMP (cAMP). This inhibition results in increased intracellular cAMP levels, causing bronchodilation and anti-inflammatory effects. Therefore, while theophylline does lead to increased cAMP levels, it does so by preventing its degradation rather than increasing its formation.",
      "correct_choice_id": 246126,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81214,
      "choices": [
        {
          "id": 246127,
          "text": "Ipratropium bromide"
        },
        {
          "id": 246128,
          "text": "Formoterol"
        },
        {
          "id": 246129,
          "text": "Salmeterol"
        },
        {
          "id": 246130,
          "text": "Indacaterol"
        }
      ],
      "text": "Which of the following is delivered as an aerosol formulation through a dry powder inhaler.",
      "unique_key": "Q6061655",
      "question_audio": null,
      "question_video": null,
      "map_id": 34886081,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) Inhibit the acetylation of core histones. Methylxanthines, such as theophylline, do not inhibit the acetylation of core histones. Instead, they are known to activate histone deacetylase (HDAC) enzymes, particularly HDAC2. Activation of HDAC leads to deacetylation of histones, resulting in a more condensed chromatin structure and suppression of inflammatory gene expression. This mechanism contributes to their anti-inflammatory effects and the restoration of steroid responsiveness in patients with chronic obstructive pulmonary disease (COPD). ATSJOURNALS.ORG Explanation of the Correct Options: (B) Induction of histone deacetylase This statement is correct. Methylxanthines induce the activity of histone deacetylases, leading to deacetylation of histones and suppression of pro-inflammatory gene expression. This action contributes to their anti-inflammatory properties. ATSJOURNALS.ORG (C) Anti-inflammatory action This statement is correct. Through mechanisms such as HDAC activation and phosphodiesterase inhibition, methylxanthines exhibit anti-inflammatory effects, which are beneficial in managing respiratory conditions like asthma and COPD. ATSJOURNALS.ORG (D) Restore steroid responsiveness in COPD patients This statement is correct. By activating histone deacetylases, methylxanthines can restore corticosteroid sensitivity in COPD patients, enhancing the efficacy of steroid treatments.",
      "correct_choice_id": 246130,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/69220441700124520/69220441700124520.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/69220441700124520/69220441700124520.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81215,
      "choices": [
        {
          "id": 246131,
          "text": "Ventilation Perfusion mismatch"
        },
        {
          "id": 246132,
          "text": "Right to left shunt"
        },
        {
          "id": 246133,
          "text": "CO2 excess"
        },
        {
          "id": 246134,
          "text": "Faulty pulse oxymeter"
        }
      ],
      "text": "A child with known case of bronchial asthma comes with respiratory distress with respiratory rate 48/min, cannot speak two words, occasional wheeze and oxygen saturation is 95%. You have given 3 doses of salbutamol by nebulization and patient get stabilised and now able to speak a sentence but oxygen saturation falls to 85% . What can be the most probable reason for fall in saturation?",
      "unique_key": "Q5133028",
      "question_audio": null,
      "question_video": null,
      "map_id": 34985278,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Ventilation Perfusion mismatch. In asthma exacerbations, the bronchoconstriction and airway inflammation can lead to areas of the lung where the airflow (ventilation) is impaired, but the blood flow (perfusion) is normal. This is called a ventilation-perfusion (V/Q) mismatch, where some parts of the lung are well-perfused but not well-ventilated, leading to poor gas exchange and hypoxemia. Despite improving the ability to speak and the relief of wheezing, this mismatch can worsen after treatment (e.g., with bronchodilators like salbutamol) because opening up some of the constricted airways may also cause poorly ventilated areas of the lung to receive more blood flow without corresponding oxygenation, leading to further decreases in oxygen saturation. This explains the observed fall in oxygen saturation to 85% after initial improvement. Explanation of Incorrect Options: (B) Right to left shunt – Incorrect. A right-to-left shunt occurs when blood bypasses the lungs, typically due to congenital heart defects (e.g., tetralogy of Fallot or atrial septal defect), leading to systemic hypoxemia. While this can cause low oxygen saturation, the clinical presentation here does not suggest a congenital heart defect or a right-to-left shunt. Additionally, the oxygen saturation did not fall immediately after salbutamol administration but rather after the initial improvement, which is more consistent with a ventilation-perfusion mismatch in the lungs rather than a structural heart defect. (C) CO2 excess – Incorrect. CO2 excess (or hypercapnia) typically occurs in conditions where there is impaired ventilation, such as chronic obstructive pulmonary disease (COPD) or in severe asthma where air trapping leads to an accumulation of carbon dioxide. However, in this scenario, the child’s oxygen saturation dropped to 85%, not because of an elevated CO2 level (which could lead to respiratory acidosis and confusion or somnolence), but due to issues in oxygenation. A primary problem with oxygenation would more likely be related to a V/Q mismatch rather than CO2 excess. (D) Faulty pulse oximeter – Incorrect. While it's always possible that the pulse oximeter could malfunction, the clinical findings here (rapid respiratory rate, wheezing, and improvement with salbutamol) and the context of asthma exacerbation make it unlikely that a faulty pulse oximeter is the cause. The fall in oxygen saturation is more likely due to a physiological cause, such as ventilation-perfusion mismatch, rather than a technical error with the equipment. Furthermore, a pulse oximeter is usually reliable in measuring oxygen saturation unless there are specific factors (e.g., poor circulation, motion, or cold extremities), which don't seem to be indicated in this case.",
      "correct_choice_id": 246131,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52271061700304713/52271061700304713.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/52271061700304713/52271061700304713.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81216,
      "choices": [
        {
          "id": 246135,
          "text": "Cough becomes more productive"
        },
        {
          "id": 246136,
          "text": "Cough stops altogether"
        },
        {
          "id": 246137,
          "text": "Fever diminishes"
        },
        {
          "id": 246138,
          "text": "Headache resolves"
        }
      ],
      "text": "Concerned mother of a 6-year-old boy takes her son to the medical officer at PHC, she complains that her son has developed a cough, stuffy nose, headache, and fever for 2 days. Medical officer prescribes a cough syrup containing guaifenesin. Which of the following effects is likely caused by guaifenesin?",
      "unique_key": "Q1062246",
      "question_audio": null,
      "question_video": null,
      "map_id": 34476906,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Cough becomes more productive. Guaifenesin is an expectorant that helps to loosen and thin mucus in the airways, making it easier for the patient to cough up phlegm. It does not suppress the cough reflex but instead makes the cough more productive, helping clear mucus from the respiratory tract. In this 6-year-old boy with cough, stuffy nose, headache, and fever, the cough is likely due to a viral upper respiratory tract infection (URTI). Guaifenesin aids mucus clearance, making the cough more effective rather than stopping it completely. Explanation of Incorrect Options: (B) Cough stops altogether Incorrect because guaifenesin does not suppress the cough reflex. Antitussives like dextromethorphan or codeine are used to suppress coughing, but guaifenesin only thins mucus to make coughing more effective. (C) Fever diminishes Incorrect because guaifenesin does not have antipyretic (fever-reducing) properties. Fever is best treated with antipyretics like paracetamol or ibuprofen, not expectorants. (D) Headache resolves Incorrect because guaifenesin does not have analgesic properties. The child's headache is likely due to fever and nasal congestion, which would improve with proper hydration, rest, and fever management, rather than guaifenesin.",
      "correct_choice_id": 246135,
      "solution_audio": null,
      "solution_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/41257341700305915/41257341700305915.m3u8",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "https://d2enu63wt1sf3u.cloudfront.net/dqb_vod/41257341700305915/41257341700305915.m3u8",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81217,
      "choices": [
        {
          "id": 246139,
          "text": "Inhaled corticosteroid (ICS)"
        },
        {
          "id": 246140,
          "text": "Short-acting beta-agonist (SABA)"
        },
        {
          "id": 246141,
          "text": "Methylxanthine"
        },
        {
          "id": 246142,
          "text": "Leukotriene receptor antagonist"
        }
      ],
      "text": "A 65-year-old male with a history of chronic obstructive pulmonary disease (COPD) presents to the clinic for routine follow-up. He is currently taking a long-acting beta-agonist (LABA) and a long-acting anticholinergic. His symptoms of dyspnea have improved, but he still experiences occasional wheezing. The physician considers adding a medication to further control his symptoms. Which of the following medications is the best option to add to this patient’s regimen?",
      "unique_key": "Q8977271",
      "question_audio": null,
      "question_video": null,
      "map_id": 34693775,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Inhaled corticosteroid (ICS). In patients with chronic obstructive pulmonary disease (COPD) who continue to experience symptoms despite treatment with a long-acting beta-agonist (LABA) and a long-acting anticholinergic (LAMA), the addition of an inhaled corticosteroid (ICS) is recommended. This combination, known as triple therapy (LABA/LAMA/ICS), has been shown to improve lung function, reduce symptoms, and decrease the frequency of exacerbations in COPD patients. PMC.NCBI.NLM.NIH.GOV Explanation of the Incorrect Options: (B) Short-acting beta-agonist (SABA): While SABAs, such as albuterol, are effective for quick relief of acute bronchospasm, they are not suitable for regular maintenance therapy in COPD. Their short duration of action necessitates frequent dosing, and they do not provide the sustained symptom control needed for chronic management. Therefore, SABAs are typically reserved for as-needed use during acute symptom flare-ups rather than as an addition to maintenance therapy. (C) Methylxanthine: Methylxanthines, like theophylline, have bronchodilator properties but are less commonly used in COPD management due to their narrow therapeutic index and potential for significant side effects, including cardiac arrhythmias and seizures. Additionally, their efficacy is modest compared to other available therapies. Consequently, methylxanthines are generally considered only when other treatments are insufficient or not tolerated. (D) Leukotriene receptor antagonist: Leukotriene receptor antagonists, such as montelukast, are primarily used in the management of asthma and have limited evidence supporting their efficacy in COPD. They are not typically included in standard COPD treatment guidelines and are not recommended for routine use in COPD management.",
      "correct_choice_id": 246139,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81218,
      "choices": [
        {
          "id": 246143,
          "text": "Oral corticosteroids"
        },
        {
          "id": 246144,
          "text": "Antihistamines"
        },
        {
          "id": 246145,
          "text": "Long-acting beta-agonists"
        },
        {
          "id": 246146,
          "text": "Intravenous magnesium sulfate"
        }
      ],
      "text": "A 30-year-old female with asthma comes to the emergency department due to an acute exacerbation. She has been using her albuterol inhaler more frequently but is still experiencing significant wheezing and shortness of breath. After administering a nebulized SABA, the physician considers systemic treatment options. Which of the following medications would be the most appropriate choice for immediate control of this patient's acute exacerbation?",
      "unique_key": "Q6767243",
      "question_audio": null,
      "question_video": null,
      "map_id": 34311552,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Oral corticosteroids. In the management of acute asthma exacerbations, systemic corticosteroids are a cornerstone of therapy due to their potent anti-inflammatory effects. They work by reducing airway inflammation, decreasing mucus production, and enhancing the effectiveness of β2-agonists. Administering systemic corticosteroids early in the course of an exacerbation can lead to faster resolution of symptoms, reduced rates of hospital admission, and decreased likelihood of relapse. Oral corticosteroids, such as prednisone or prednisolone, are commonly used because they are effective, easy to administer, and have a rapid onset of action. A typical course lasts from 3 to 5 days, depending on the severity of the exacerbation and the patient's response to treatment. Incorrect Options: (B) Antihistamines Antihistamines are primarily used to manage allergic reactions by blocking histamine receptors. While they can be beneficial in controlling allergic symptoms, they are not effective in the acute management of asthma exacerbations. They do not provide rapid bronchodilation or significant anti-inflammatory effects necessary to address the acute airway obstruction and inflammation seen in asthma attacks. (C) Long-acting beta-agonists (LABAs) LABAs, such as salmeterol and formoterol, are used for long-term control of asthma symptoms and are not suitable for acute symptom relief due to their slower onset of action. In acute exacerbations, short-acting beta-agonists (SABAs) like albuterol are preferred for rapid bronchodilation. Moreover, LABAs should always be used in combination with inhaled corticosteroids in asthma management to mitigate the risk of asthma-related adverse events. (D) Intravenous magnesium sulfate Intravenous magnesium sulfate can be used as an adjunct therapy in severe asthma exacerbations that are unresponsive to initial treatments. It acts as a bronchodilator by inhibiting calcium influx into airway smooth muscle cells. However, it is not considered a first-line treatment and is typically reserved for cases where standard therapies, including inhaled bronchodilators and systemic corticosteroids, have failed to achieve adequate control.",
      "correct_choice_id": 246143,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81219,
      "choices": [
        {
          "id": 246147,
          "text": "Discontinue the inhaled corticosteroid"
        },
        {
          "id": 246148,
          "text": "Rinse her mouth after using the inhaler"
        },
        {
          "id": 246149,
          "text": "Switch to a short-acting beta-agonist"
        },
        {
          "id": 246150,
          "text": "Increase the dose of the inhaled corticosteroid"
        }
      ],
      "text": "A 55-year-old woman with a history of asthma presents for a routine follow-up. She is currently using a combination inhaler containing a long-acting beta-agonist and an inhaled corticosteroid. Upon review of her medication, she mentions she has been experiencing thrush and hoarseness. What is the most appropriate recommendation for this patient?",
      "unique_key": "Q9484037",
      "question_audio": null,
      "question_video": null,
      "map_id": 34731201,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Rinse her mouth after using the inhaler. Inhaled corticosteroids (ICS), commonly used in combination with long-acting beta-agonists (LABAs) for asthma management, can lead to local side effects such as oropharyngeal candidiasis (thrush) and dysphonia (hoarseness). These adverse effects are primarily due to the deposition of medication in the oral and pharyngeal regions during inhalation. To mitigate these side effects, it is recommended that patients rinse their mouth with water and spit it out after each inhaler use. This practice helps remove residual medication, thereby reducing the risk of thrush and irritation that can cause hoarseness. Explanation of the Incorrect Options: (A) Discontinue the inhaled corticosteroid Discontinuing the ICS is not advisable, as it plays a crucial role in controlling airway inflammation in asthma. Stopping ICS therapy could lead to worsening asthma control and increased risk of exacerbations. Instead, implementing strategies to reduce local side effects, such as proper inhaler technique and oral rinsing, is preferred. (C) Switch to a short-acting beta-agonist Short-acting beta-agonists (SABAs) are intended for quick relief of acute asthma symptoms and are not suitable for long-term control. Replacing the current maintenance therapy with a SABA would not address the underlying inflammation and could result in poor asthma control. (D) Increase the dose of the inhaled corticosteroid Increasing the ICS dose may exacerbate the local side effects and is unlikely to alleviate the symptoms of thrush and hoarseness. The focus should be on minimizing side effects through proper inhaler use and oral hygiene practices.",
      "correct_choice_id": 246148,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81220,
      "choices": [
        {
          "id": 246151,
          "text": "Albuterol"
        },
        {
          "id": 246152,
          "text": "Salmeterol"
        },
        {
          "id": 246153,
          "text": "Formoterol"
        },
        {
          "id": 246154,
          "text": "Isoproterenol"
        }
      ],
      "text": "A 70-year-old male with a history of asthma and hypertension is prescribed a new medication for his asthma. Upon reviewing his medication history, the pharmacist notes that the new medication, a beta-agonist, could potentially interact with his antihypertensive medication. Which of the following beta-agonists is least likely to cause significant cardiovascular side effects?",
      "unique_key": "Q5578344",
      "question_audio": null,
      "question_video": null,
      "map_id": 34059698,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Albuterol. Albuterol, also known as salbutamol, is a short-acting β2-adrenergic agonist (SABA) commonly used for the relief of acute asthma symptoms. Due to its high selectivity for β2-adrenergic receptors predominantly found in the bronchial smooth muscle, albuterol effectively induces bronchodilation with minimal cardiovascular side effects. While some patients may experience transient tachycardia or palpitations, these effects are generally mild and less pronounced compared to less selective β2-agonists. Therefore, albuterol is considered the preferred β-agonist for patients with asthma and coexisting cardiovascular conditions, such as hypertension. Explanation of the Incorrect Options: (B) Salmeterol Salmeterol is a long-acting β2-adrenergic agonist (LABA) used for maintenance therapy in asthma and chronic obstructive pulmonary disease (COPD). Although it is selective for β2-receptors, its prolonged duration of action may increase the risk of cardiovascular side effects, especially if not used in combination with inhaled corticosteroids. Therefore, it is not typically used for acute symptom relief and may pose a higher risk of cardiovascular effects compared to albuterol. (C) Formoterol Formoterol is another LABA with a faster onset of action compared to salmeterol but is still primarily used for long-term control rather than acute relief. Similar to salmeterol, formoterol's extended duration of action may be associated with an increased risk of cardiovascular side effects, particularly if not combined with inhaled corticosteroids. (D) Isoproterenol Isoproterenol is a non-selective β-adrenergic agonist that stimulates both β1 and β2 receptors. Its lack of selectivity leads to significant cardiovascular effects, including increased heart rate, arrhythmias, and potential for myocardial ischemia. Due to these pronounced cardiovascular side effects, isoproterenol is generally avoided in patients with cardiovascular conditions and is not commonly used for asthma management.",
      "correct_choice_id": 246151,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81221,
      "choices": [
        {
          "id": 246155,
          "text": "Tachycardia"
        },
        {
          "id": 246156,
          "text": "Oral candidiasis"
        },
        {
          "id": 246157,
          "text": "Hypokalemia"
        },
        {
          "id": 246158,
          "text": "Insomnia"
        }
      ],
      "text": "A 40-year-old woman with asthma is being treated with a combination inhaler that includes a long-acting beta-agonist (LABA) and an inhaled corticosteroid (ICS). She reports that her asthma symptoms are well-controlled but is concerned about potential side effects of her medication. Which of the following side effects is most commonly associated with the use of inhaled corticosteroids?",
      "unique_key": "Q3639234",
      "question_audio": null,
      "question_video": null,
      "map_id": 34489746,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Oral candidiasis. Oral candidiasis, also known as thrush, is a common side effect associated with the use of inhaled corticosteroids (ICS). ICS can suppress local immunity in the oral cavity, leading to an overgrowth of the fungus Candida, which manifests as white patches, redness, and soreness in the mouth. To minimize this risk, it is recommended to rinse the mouth with water and spit it out after inhaling the medication. Using a spacer device with a metered-dose inhaler can also help reduce the deposition of the medication in the oropharyngeal area, thereby decreasing the likelihood of developing thrush. NHS.UK Explanation of the Incorrect Options: (A) Tachycardia Tachycardia, or increased heart rate, is more commonly associated with beta-agonists, particularly short-acting beta-agonists (SABAs) like albuterol, rather than with inhaled corticosteroids. While some combination inhalers contain both ICS and long-acting beta-agonists (LABAs), the tachycardia would be attributed to the LABA component rather than the corticosteroid. (C) Hypokalemia Hypokalemia, or low potassium levels, can occur with high doses of beta-agonists due to their effect on beta-2 receptors, which can drive potassium into cells. Inhaled corticosteroids alone are not typically associated with significant changes in potassium levels. (D) Insomnia Insomnia is not a common side effect of inhaled corticosteroids. Systemic corticosteroids, especially when taken in higher doses or in the evening, can disrupt sleep patterns. However, the systemic absorption of inhaled corticosteroids is minimal when used at recommended doses, making insomnia an unlikely side effect.",
      "correct_choice_id": 246156,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81222,
      "choices": [
        {
          "id": 246159,
          "text": "Theophylline"
        },
        {
          "id": 246160,
          "text": "Inhaled corticosteroid"
        },
        {
          "id": 246161,
          "text": "Short-acting beta-agonist"
        },
        {
          "id": 246162,
          "text": "Mucolytic agent"
        }
      ],
      "text": "A 68-year-old male with COPD presents to the emergency department with worsening dyspnea. He is currently on a long-acting anticholinergic (tiotropium) and a LABA (salmeterol). The physician decides to add a medication to reduce his frequency of exacerbations. Which of the following medications is most appropriate for this patient?",
      "unique_key": "Q1078253",
      "question_audio": null,
      "question_video": null,
      "map_id": 34663425,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Inhaled corticosteroid. In patients with chronic obstructive pulmonary disease (COPD) who continue to experience exacerbations despite treatment with a long-acting anticholinergic (LAMA) like tiotropium and a long-acting beta-agonist (LABA) such as salmeterol, the addition of an inhaled corticosteroid (ICS) is recommended. This combination, known as triple therapy (LABA/LAMA/ICS), has been shown to reduce the frequency of exacerbations and improve lung function and health status in patients with COPD. PMC.NCBI.NLM.NIH.GOV Explanation of the Incorrect Options: (A) Theophylline Theophylline is a methylxanthine bronchodilator that has been used in COPD management. However, its use is limited due to a narrow therapeutic index, potential for significant side effects, and the need for serum level monitoring. Current guidelines generally reserve theophylline for cases where other treatments are insufficient or not tolerated. (C) Short-acting beta-agonist (SABA) Short-acting beta-agonists, such as albuterol, are effective for quick relief of acute bronchospasm but are not suitable for regular maintenance therapy in COPD. Their short duration of action necessitates frequent dosing, and they do not provide the sustained symptom control needed for chronic management. Therefore, SABAs are typically reserved for as-needed use during acute symptom flare-ups rather than as an addition to maintenance therapy. (D) Mucolytic agent Mucolytic agents help thin and loosen mucus in the airways, which can be beneficial for some COPD patients, particularly those with chronic bronchitis and significant mucus production. However, they are not the primary choice for reducing exacerbation frequency and are generally considered adjunctive therapy. Their efficacy in preventing exacerbations is less established compared to inhaled corticosteroids.",
      "correct_choice_id": 246160,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81223,
      "choices": [
        {
          "id": 246163,
          "text": "Inhibition of phosphodiesterase"
        },
        {
          "id": 246164,
          "text": "Blockade of beta-2 adrenergic receptors"
        },
        {
          "id": 246165,
          "text": "Antagonism of leukotriene receptors"
        },
        {
          "id": 246166,
          "text": "Stabilization of mast cells"
        }
      ],
      "text": "A 25-year-old male with asthma is prescribed montelukast, a leukotriene receptor antagonist, to help manage his symptoms. Which of the following best describes the mechanism of action of montelukast?",
      "unique_key": "Q7933206",
      "question_audio": null,
      "question_video": null,
      "map_id": 34598663,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Antagonism of leukotriene receptors. Montelukast is a leukotriene receptor antagonist that works by selectively binding to cysteinyl leukotriene type-1 (CysLT1) receptors. By blocking these receptors, montelukast inhibits the physiological actions of leukotrienes, which are inflammatory mediators involved in asthma pathophysiology. This antagonism leads to reduced airway edema, smooth muscle contraction, and inflammation, thereby helping to manage asthma symptoms. NCBI.NLM.NIH.GOV Explanation of the Incorrect Options: (A) Inhibition of phosphodiesterase This is incorrect. Inhibition of phosphodiesterase (PDE) is the mechanism of action for drugs like theophylline, which increase cyclic AMP levels leading to bronchodilation. Montelukast does not inhibit PDE; instead, it targets leukotriene receptors. (B) Blockade of beta-2 adrenergic receptors This is incorrect. Beta-2 adrenergic receptor blockers are typically used in cardiovascular conditions and are not involved in asthma management. Montelukast does not block beta-2 receptors; it antagonizes leukotriene receptors to exert its effects. (D) Stabilization of mast cells This is incorrect. Mast cell stabilizers, such as cromolyn sodium, prevent the release of inflammatory mediators from mast cells. Montelukast does not stabilize mast cells; it works by blocking the action of leukotrienes on their receptors.",
      "correct_choice_id": 246165,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81224,
      "choices": [
        {
          "id": 246167,
          "text": "Formoterol"
        },
        {
          "id": 246168,
          "text": "Salmeterol"
        },
        {
          "id": 246169,
          "text": "Indacaterol"
        },
        {
          "id": 246170,
          "text": "Arformoterol"
        }
      ],
      "text": "A 72-year-old woman with a history of asthma and hypertension is prescribed a new inhaler that contains a long-acting beta-agonist. During the follow-up visit, she reports increased heart rate and palpitations. Which of the following long-acting beta-agonists is considered to have the least cardiovascular side effects?",
      "unique_key": "Q8475823",
      "question_audio": null,
      "question_video": null,
      "map_id": 34764041,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Salmeterol. Salmeterol is a long-acting β2-adrenergic agonist (LABA) known for its high selectivity for β2-receptors and prolonged duration of action. Its unique molecular structure includes a long, lipophilic side chain that binds to an exosite near the β2-receptor, allowing for continuous activation while minimizing systemic absorption. This design contributes to a lower incidence of cardiovascular side effects, such as tachycardia and palpitations, compared to other LABAs. Clinical studies have indicated that salmeterol, when used appropriately, does not significantly increase the risk of cardiovascular events in patients with asthma or chronic obstructive pulmonary disease Explanation of the Incorrect Options: (A) Formoterol Formoterol is another LABA with rapid onset and high β2-receptor selectivity. However, its faster onset of action and higher intrinsic activity may lead to more pronounced cardiovascular effects, such as increased heart rate and palpitations, especially if not used in combination with inhaled corticosteroids. (C) Indacaterol Indacaterol is an ultra-long-acting β2-agonist used primarily in COPD management. While effective in providing sustained bronchodilation, indacaterol has been associated with dose-dependent cardiovascular side effects, including tachycardia and hypertension, due to its potent β2-agonist activity. (D) Arformoterol Arformoterol is the (R,R)-enantiomer of formoterol and is used as a long-acting bronchodilator in COPD patients. Despite its efficacy, arformoterol may cause cardiovascular side effects such as palpitations and increased heart rate, particularly in susceptible individuals.",
      "correct_choice_id": 246168,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81225,
      "choices": [
        {
          "id": 246171,
          "text": "Weight loss"
        },
        {
          "id": 246172,
          "text": "Osteoporosis"
        },
        {
          "id": 246173,
          "text": "Increased respiratory infections"
        },
        {
          "id": 246174,
          "text": "Hyperkalemia"
        }
      ],
      "text": "A 50-year-old man with severe asthma is being treated with high-dose inhaled corticosteroids and long-acting beta-agonists. He reports frequent exacerbations and has been prescribed a course of oral corticosteroids. What is the primary concern with long-term use of oral corticosteroids in this patient?",
      "unique_key": "Q7296396",
      "question_audio": null,
      "question_video": null,
      "map_id": 34334875,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Osteoporosis. Long-term use of oral corticosteroids, such as prednisone, is associated with several significant side effects, among which osteoporosis is particularly concerning. Corticosteroids can lead to decreased bone formation and increased bone resorption, resulting in reduced bone density and an elevated risk of fractures. Studies indicate that up to 40% of patients on long-term glucocorticoid therapy develop bone loss leading to fractures. NCBI.NLM.NIH.GOV Explanation of the Incorrect Options: (A) Weight loss This is incorrect. Corticosteroids are more commonly associated with weight gain rather than weight loss. They can increase appetite and cause fluid retention, leading to weight gain. Additionally, fat redistribution can occur, resulting in characteristic features such as \"moon face\" and \"buffalo hump.\" MAYOCLINIC.ORG (C) Increased respiratory infections This is incorrect. While corticosteroids can suppress the immune system, increasing the risk of infections, they are not specifically associated with an increased risk of respiratory infections. The immunosuppressive effects can make individuals more susceptible to various types of infections, but respiratory infections are not uniquely prevalent. MAYOCLINIC.ORG (D) Hyperkalemia This is incorrect. Corticosteroids are more likely to cause hypokalemia (low potassium levels) rather than hyperkalemia. They can promote the excretion of potassium, leading to decreased potassium levels in the blood.",
      "correct_choice_id": 246172,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81226,
      "choices": [
        {
          "id": 246175,
          "text": "Acetylcysteine"
        },
        {
          "id": 246176,
          "text": "Budesonide"
        },
        {
          "id": 246177,
          "text": "Albuterol"
        },
        {
          "id": 246178,
          "text": "Tiotropium"
        }
      ],
      "text": "A 45-year-old female with COPD presents with persistent cough and excessive mucus production. The physician prescribes a mucolytic agent to help manage her symptoms. Which of the following medications is a commonly used mucolytic?",
      "unique_key": "Q9787173",
      "question_audio": null,
      "question_video": null,
      "map_id": 34175617,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Acetylcysteine. Acetylcysteine, also known as N-acetylcysteine (NAC), is a commonly used mucolytic agent that helps manage respiratory conditions characterized by excessive or thick mucus, such as chronic obstructive pulmonary disease (COPD). It works by breaking down the disulfide bonds in mucus proteins, thereby reducing the viscosity of the mucus and making it easier to expectorate. This action helps alleviate symptoms like persistent cough and facilitates better airway clearance. MY.CLEVELANDCLINIC.ORG Explanation of the Incorrect Options: (B) Budesonide Budesonide is an inhaled corticosteroid (ICS) used to reduce airway inflammation in conditions like asthma and COPD. While effective in controlling inflammation, it does not possess mucolytic properties and therefore does not directly address mucus viscosity or facilitate its clearance. (C) Albuterol Albuterol is a short-acting beta-agonist (SABA) that acts as a bronchodilator, relaxing the smooth muscles of the airways to improve airflow. It is primarily used for quick relief of bronchospasm in asthma and COPD but does not have mucolytic effects to reduce mucus thickness or aid in its clearance. (D) Tiotropium Tiotropium is a long-acting anticholinergic bronchodilator used in the management of COPD. It helps to relax and open the airways, improving airflow and reducing symptoms like shortness of breath. However, it does not possess mucolytic properties and does not directly affect mucus consistency or clearance.",
      "correct_choice_id": 246175,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81227,
      "choices": [
        {
          "id": 246179,
          "text": "Dextromethorphan"
        },
        {
          "id": 246180,
          "text": "Guaifenesin"
        },
        {
          "id": 246181,
          "text": "Benzonatate"
        },
        {
          "id": 246182,
          "text": "Diphenhydramine"
        }
      ],
      "text": "A 60-year-old male with a history of chronic bronchitis presents with a persistent cough that produces thick sputum. He has been using albuterol as a rescue inhaler. The physician decides to prescribe a medication to help with his cough and mucus clearance. Which of the following medications is most appropriate for this patient?",
      "unique_key": "Q6825276",
      "question_audio": null,
      "question_video": null,
      "map_id": 34203588,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Guaifenesin. Guaifenesin is an expectorant commonly used to manage symptoms associated with respiratory conditions characterized by excessive mucus production, such as chronic bronchitis. It works by thinning and loosening mucus in the airways, making it easier to cough up the phlegm and clear the airways. This action helps alleviate persistent cough and facilitates better breathing. PMC.NCBI.NLM.NIH.GOV Explanation of the Incorrect Options: (A) Dextromethorphan Dextromethorphan is a cough suppressant that acts on the brain to suppress the cough reflex. While it can be effective in reducing cough frequency, it does not address the underlying issue of mucus production or aid in mucus clearance. In cases of chronic bronchitis with thick sputum, suppressing the cough reflex may lead to mucus accumulation, which can worsen respiratory symptoms. (C) Benzonatate Benzonatate is another cough suppressant that works by numbing the throat and lungs, reducing the cough reflex. Similar to dextromethorphan, it does not have expectorant properties and does not assist in thinning or clearing mucus from the airways. Using benzonatate in a patient with productive cough and thick sputum may hinder mucus clearance. (D) Diphenhydramine Diphenhydramine is an antihistamine with sedative properties and is sometimes used as a cough suppressant. However, it also has anticholinergic effects, which can lead to drying of respiratory secretions, making mucus thicker and more difficult to expel. Therefore, it is not suitable for patients with chronic bronchitis who need to clear mucus from their airways.",
      "correct_choice_id": 246180,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81228,
      "choices": [
        {
          "id": 246183,
          "text": "Sildenafil"
        },
        {
          "id": 246184,
          "text": "Bosentan"
        },
        {
          "id": 246185,
          "text": "Epoprostenol"
        },
        {
          "id": 246186,
          "text": "Ambrisentan"
        }
      ],
      "text": "A 45-year-old woman with pulmonary arterial hypertension (PAH) is prescribed a medication to improve her exercise tolerance and quality of life. Which of the following drugs is a prostacyclin analog used in the treatment of PAH?",
      "unique_key": "Q3660077",
      "question_audio": null,
      "question_video": null,
      "map_id": 34847943,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Epoprostenol. Epoprostenol is a prostacyclin analog used in the treatment of pulmonary arterial hypertension (PAH). It mimics the effects of naturally occurring prostacyclin (PGI?), leading to vasodilation of the pulmonary arteries, inhibition of platelet aggregation, and antiproliferative effects on vascular smooth muscle cells. These actions help reduce pulmonary vascular resistance and improve exercise capacity in patients with PAH. Epoprostenol is typically administered as a continuous intravenous infusion due to its short half-life. NCBI.NLM.NIH.GOV Explanation of the Incorrect Options: (A) Sildenafil Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor used in PAH treatment. It works by increasing cyclic guanosine monophosphate (cGMP) levels, leading to vasodilation of the pulmonary arteries. However, it is not a prostacyclin analog. (B) Bosentan Bosentan is an endothelin receptor antagonist that blocks the effects of endothelin-1, a potent vasoconstrictor, thereby promoting vasodilation in PAH patients. It is not classified as a prostacyclin analog. (D) Ambrisentan Ambrisentan is also an endothelin receptor antagonist that selectively blocks the endothelin-A receptor, resulting in vasodilation. Like bosentan, it is not a prostacyclin analog.",
      "correct_choice_id": 246185,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81229,
      "choices": [
        {
          "id": 246187,
          "text": "Liver function abnormalities"
        },
        {
          "id": 246188,
          "text": "Hypertension"
        },
        {
          "id": 246189,
          "text": "Weight gain"
        },
        {
          "id": 246190,
          "text": "Bradycardia"
        }
      ],
      "text": "A 52-year-old male with pulmonary hypertension is initiated on bosentan. What is a significant adverse effect of bosentan that requires monitoring?",
      "unique_key": "Q6257789",
      "question_audio": null,
      "question_video": null,
      "map_id": 34525273,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Liver function abnormalities. Bosentan is an endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. A significant adverse effect of bosentan is hepatotoxicity, which manifests as elevations in liver aminotransferase levels (ALT and AST). In clinical trials, approximately 11% of patients treated with bosentan experienced increases in liver enzymes. Due to this risk, it is essential to monitor liver function tests prior to initiating therapy and monthly thereafter. If significant liver enzyme elevations occur, dose adjustments or discontinuation of the medication may be necessary. ACCESSDATA.FDA.GOV Explanation of the Incorrect Options: (B) Hypertension This is incorrect. Bosentan is primarily used to manage pulmonary arterial hypertension by promoting vasodilation, which can lead to a decrease in blood pressure. Hypertension is not a common adverse effect associated with bosentan; in fact, hypotension (low blood pressure) may occur in some patients. (C) Weight gain This is incorrect. While bosentan can cause fluid retention leading to peripheral edema, significant weight gain is not commonly reported as a direct adverse effect. Patients should be monitored for signs of fluid retention, but weight gain is not a primary concern. (D) Bradycardia This is incorrect. Bradycardia (slow heart rate) is not commonly associated with bosentan therapy. The medication's vasodilatory effects do not typically impact heart rate to the extent of causing bradycardia.",
      "correct_choice_id": 246187,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81230,
      "choices": [
        {
          "id": 246191,
          "text": "Liver function abnormalities"
        },
        {
          "id": 246192,
          "text": "Hypertension"
        },
        {
          "id": 246193,
          "text": "Weight gain"
        },
        {
          "id": 246194,
          "text": "Bradycardia"
        }
      ],
      "text": "A 52-year-old male with pulmonary hypertension is initiated on bosentan. What is a significant adverse effect of bosentan that requires monitoring?",
      "unique_key": "Q7318286",
      "question_audio": null,
      "question_video": null,
      "map_id": 34487688,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Liver function abnormalities. Bosentan is an endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. A significant adverse effect of bosentan is hepatotoxicity, which manifests as elevations in liver aminotransferase levels (ALT and AST). In clinical trials, approximately 11% of patients treated with bosentan experienced increases in liver enzymes. Due to this risk, it is essential to monitor liver function tests prior to initiating therapy and monthly thereafter. If significant liver enzyme elevations occur, dose adjustments or discontinuation of the medication may be necessary. ACCESSDATA.FDA.GOV Explanation of the Incorrect Options: (B) Hypertension This is incorrect. Bosentan is primarily used to manage pulmonary arterial hypertension by promoting vasodilation, which can lead to a decrease in blood pressure. Hypertension is not a common adverse effect associated with bosentan; in fact, hypotension (low blood pressure) may occur in some patients. (C) Weight gain This is incorrect. While bosentan can cause fluid retention leading to peripheral edema, significant weight gain is not commonly reported as a direct adverse effect. Patients should be monitored for signs of fluid retention, but weight gain is not a primary concern. (D) Bradycardia This is incorrect. Bradycardia (slow heart rate) is not commonly associated with bosentan therapy. The medication's vasodilatory effects do not typically impact heart rate to the extent of causing bradycardia.",
      "correct_choice_id": 246191,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81231,
      "choices": [
        {
          "id": 246195,
          "text": "Loratadine"
        },
        {
          "id": 246196,
          "text": "Diphenhydramine"
        },
        {
          "id": 246197,
          "text": "Fexofenadine"
        },
        {
          "id": 246198,
          "text": "Cetirizine"
        }
      ],
      "text": "A patient with chronic cough due to post-nasal drip is prescribed a medication to help relieve her symptoms. Which of the following medications is an antihistamine that may also help with her cough?",
      "unique_key": "Q2309466",
      "question_audio": null,
      "question_video": null,
      "map_id": 34278028,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Diphenhydramine. Diphenhydramine is a first-generation antihistamine that can be effective in managing cough associated with post-nasal drip. Its anticholinergic properties help dry up nasal secretions, reducing the post-nasal drip that often triggers cough. Additionally, diphenhydramine has a sedative effect, which can suppress the cough reflex and provide symptomatic relief. However, due to its sedative nature, it may cause drowsiness, so caution is advised when using it, especially during activities that require alertness. HEALTH.HARVARD.EDU Explanation of the Incorrect Options: (A) Loratadine Loratadine is a second-generation antihistamine that is non-sedating and primarily used to treat allergic symptoms. While it can help reduce nasal congestion and runny nose, it is less effective in drying up nasal secretions compared to first-generation antihistamines like diphenhydramine. Therefore, it may not be as effective in managing cough due to post-nasal drip. HEALTH.HARVARD.EDU (C) Fexofenadine Fexofenadine is another second-generation antihistamine that is non-sedating and used to relieve allergy symptoms. Similar to loratadine, it is less effective in reducing nasal secretions and may not provide significant relief for cough associated with post-nasal drip. HEALTH.HARVARD.EDU (D) Cetirizine Cetirizine is a second-generation antihistamine that is minimally sedating and used to treat allergic symptoms. While it can help with nasal congestion, it does not have the anticholinergic properties necessary to effectively reduce nasal secretions and manage cough due to post-nasal drip.",
      "correct_choice_id": 246196,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81232,
      "choices": [
        {
          "id": 246199,
          "text": "Montelukast"
        },
        {
          "id": 246200,
          "text": "Salbutamol (albuterol)"
        },
        {
          "id": 246201,
          "text": "Theophylline"
        },
        {
          "id": 246202,
          "text": "Budesonide"
        }
      ],
      "text": "A 30-year-old female diagnosed with exercise-induced bronchospasm is prescribed a medication to take before exercise. Which of the following medications is most effective for this purpose?",
      "unique_key": "Q5372529",
      "question_audio": null,
      "question_video": null,
      "map_id": 34396369,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Salbutamol (albuterol). Salbutamol, also known as albuterol, is a short-acting β2-adrenergic agonist (SABA) commonly used to prevent and treat exercise-induced bronchospasm (EIB). When inhaled 15 to 30 minutes before exercise, salbutamol effectively relaxes bronchial smooth muscle, leading to bronchodilation and improved airflow. Its effects typically onset within minutes and last for two to four hours, making it suitable for pre-exercise administration. This preventive strategy allows individuals with EIB to engage in physical activity with a reduced risk of bronchospasm. Explanation of the Incorrect Options: (A) Montelukast Montelukast is a leukotriene receptor antagonist that can be used to prevent EIB. However, it is generally taken daily and may not provide the immediate bronchodilation needed for acute prevention of exercise-induced symptoms. Its onset of action is slower compared to SABAs like salbutamol. (C) Theophylline Theophylline is a methylxanthine bronchodilator used for chronic asthma management. Due to its narrow therapeutic index and potential for significant side effects, it is not typically used for acute prevention of EIB. Additionally, it requires serum level monitoring and has a slower onset of action compared to inhaled SABAs. (D) Budesonide Budesonide is an inhaled corticosteroid (ICS) that helps reduce airway inflammation in asthma. While effective for long-term asthma control, ICSs do not provide the rapid bronchodilation necessary for preventing EIB immediately before exercise. They are typically used as maintenance therapy rather than for acute symptom prevention.",
      "correct_choice_id": 246200,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81233,
      "choices": [
        {
          "id": 246203,
          "text": "Ipratropium"
        },
        {
          "id": 246204,
          "text": "Tiotropium"
        },
        {
          "id": 246205,
          "text": "Albuterol"
        },
        {
          "id": 246206,
          "text": "Formoterol"
        }
      ],
      "text": "A 65-year-old female with COPD is experiencing significant coughing and mucus production. The physician considers prescribing a bronchodilator. Which of the following is classified as a long-acting anticholinergic agent?",
      "unique_key": "Q1425343",
      "question_audio": null,
      "question_video": null,
      "map_id": 34515709,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Tiotropium. Tiotropium is classified as a long-acting anticholinergic agent, also known as a long-acting muscarinic antagonist (LAMA). It is commonly prescribed for the management of chronic obstructive pulmonary disease (COPD) to help reduce bronchospasm and mucus production. Tiotropium works by blocking the action of acetylcholine on muscarinic receptors in the airway smooth muscle, leading to bronchodilation and decreased mucus secretion. Its long duration of action allows for once-daily dosing, providing sustained symptom control in COPD patients. Explanation of the Incorrect Options: (A) Ipratropium Ipratropium is an anticholinergic agent used as a bronchodilator in respiratory conditions. However, it is a short-acting muscarinic antagonist (SAMA), requiring multiple doses per day to maintain its therapeutic effect. Due to its shorter duration of action, it is not classified as a long-acting anticholinergic agent. (C) Albuterol Albuterol, also known as salbutamol, is a short-acting β2-adrenergic agonist (SABA). It provides rapid bronchodilation by stimulating β2 receptors in the airway smooth muscle but has a short duration of action, necessitating frequent dosing. Albuterol is not an anticholinergic agent and is not classified as long-acting. (D) Formoterol Formoterol is a long-acting β2-adrenergic agonist (LABA) that provides prolonged bronchodilation by stimulating β2 receptors. While it has a long duration of action, it is not an anticholinergic agent; instead, it works through adrenergic pathways.",
      "correct_choice_id": 246204,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81234,
      "choices": [
        {
          "id": 246207,
          "text": "Renal function"
        },
        {
          "id": 246208,
          "text": "Complete blood count"
        },
        {
          "id": 246209,
          "text": "Liver function tests"
        },
        {
          "id": 246210,
          "text": "Serum electrolytes"
        }
      ],
      "text": "A 55-year-old man with pulmonary hypertension is being treated with ambrisentan. Which of the following is a key monitoring parameter for patients on this medication?",
      "unique_key": "Q4363463",
      "question_audio": null,
      "question_video": null,
      "map_id": 34185070,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (C) Liver function tests. Ambrisentan is an endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension. While it has a lower incidence of liver enzyme elevations compared to other drugs in its class, monitoring liver function is still important. It is recommended to assess liver function before initiating therapy and periodically thereafter, especially if clinically indicated. Elevations in liver enzymes can occur, and in rare cases, serious liver injury has been reported. Therefore, regular monitoring of liver function tests is essential to detect potential hepatotoxicity early and manage it appropriately. GILEAD.COM Explanation of the Incorrect Options: (A) Renal function Ambrisentan is primarily metabolized by the liver, and less than 5% of the drug is excreted unchanged in the urine. Therefore, routine monitoring of renal function is not typically required unless the patient has pre-existing renal impairment or is taking other medications that may affect kidney function. PMC.NCBI.NLM.NIH.GOV (B) Complete blood count While decreases in hemoglobin and hematocrit have been observed with ambrisentan therapy, these changes are usually detected within the first few weeks of treatment and tend to stabilize thereafter. It is recommended to measure hemoglobin concentration prior to initiation, at one month, and periodically thereafter. However, liver function monitoring remains a more critical parameter due to the potential for hepatotoxicity. GILEAD.COM (D) Serum electrolytes Ambrisentan is not commonly associated with significant electrolyte disturbances. Therefore, routine monitoring of serum electrolytes is not typically necessary unless clinically indicated.",
      "correct_choice_id": 246209,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81235,
      "choices": [
        {
          "id": 246211,
          "text": "Dextromethorphan"
        },
        {
          "id": 246212,
          "text": "Guaifenesin"
        },
        {
          "id": 246213,
          "text": "Codeine"
        },
        {
          "id": 246214,
          "text": "Diphenhydramine"
        }
      ],
      "text": "A 70-year-old female with chronic cough due to COPD is treated with a combination of tiotropium and salmeterol. She asks about using over-the-counter medications to manage her cough. Which of the following over-the-counter medications is most appropriate for a productive cough?",
      "unique_key": "Q1636143",
      "question_audio": null,
      "question_video": null,
      "map_id": 34133129,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Guaifenesin. Guaifenesin is an expectorant that helps thin and loosen mucus in the airways, making it easier to cough up the phlegm associated with chronic obstructive pulmonary disease (COPD). By reducing the viscosity of bronchial secretions, guaifenesin facilitates a more productive cough, aiding in clearing the airways and improving breathing comfort. This can be particularly beneficial for individuals with COPD who experience significant coughing and mucus production. MY.CLEVELANDCLINIC.ORG Explanation of the Incorrect Options: (A) Dextromethorphan Dextromethorphan is a cough suppressant that works by inhibiting the cough reflex in the brain. While it can be effective for dry, non-productive coughs, suppressing the cough reflex in COPD patients with productive coughs is generally not recommended. In such cases, coughing serves an essential purpose by helping to clear mucus from the lungs. Therefore, using dextromethorphan could lead to mucus retention and potentially worsen respiratory function. FAMILYDOCTOR.ORG (C) Codeine Codeine is an opioid cough suppressant that reduces the urge to cough by acting on the central nervous system. Similar to dextromethorphan, codeine is more suitable for dry, non-productive coughs. Additionally, codeine can cause side effects such as constipation, drowsiness, and the potential for dependence, making it less ideal for managing cough in COPD patients. FAMILYDOCTOR.ORG (D) Diphenhydramine Diphenhydramine is an antihistamine with sedative properties and is sometimes used as a cough suppressant. However, it also has anticholinergic effects, which can lead to drying of respiratory secretions, making mucus thicker and more difficult to expel. Therefore, it is not suitable for patients with COPD who need to clear mucus from their airways.",
      "correct_choice_id": 246212,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81236,
      "choices": [
        {
          "id": 246215,
          "text": "Inhibition of phosphodiesterase-5"
        },
        {
          "id": 246216,
          "text": "Stimulation of soluble guanylate cyclase"
        },
        {
          "id": 246217,
          "text": "Endothelin receptor antagonism"
        },
        {
          "id": 246218,
          "text": "Prostaglandin analog action"
        }
      ],
      "text": "A 62-year-old man with pulmonary arterial hypertension (PAH) is started on riociguat. What is the primary mechanism of action of riociguat in treating PAH?",
      "unique_key": "Q5687829",
      "question_audio": null,
      "question_video": null,
      "map_id": 34944914,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (B) Stimulation of soluble guanylate cyclase. Riociguat is a medication used in the treatment of pulmonary arterial hypertension (PAH) that functions by stimulating soluble guanylate cyclase (sGC), an enzyme found in the cardiopulmonary system. This stimulation leads to increased production of cyclic guanosine monophosphate (cGMP), resulting in vasodilation and reduced pulmonary vascular resistance. GO.DRUGBANK.COM Explanation of the Incorrect Options: (A) Inhibition of phosphodiesterase-5 This mechanism pertains to medications like sildenafil and tadalafil, which inhibit phosphodiesterase-5 (PDE-5) to increase cGMP levels, leading to vasodilation. Riociguat, however, does not inhibit PDE-5; instead, it directly stimulates sGC. (C) Endothelin receptor antagonism Endothelin receptor antagonists, such as bosentan and ambrisentan, work by blocking the effects of endothelin-1, a potent vasoconstrictor. Riociguat does not function through endothelin receptor antagonism. (D) Prostaglandin analog action Prostaglandin analogs, like epoprostenol, mimic the effects of prostacyclin to induce vasodilation. Riociguat does not act as a prostaglandin analog.",
      "correct_choice_id": 246216,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81237,
      "choices": [
        {
          "id": 246219,
          "text": "Indacaterol/glycopyrrolate"
        },
        {
          "id": 246220,
          "text": "Salmeterol/fluticasone"
        },
        {
          "id": 246221,
          "text": "Formoterol/budesonide"
        },
        {
          "id": 246222,
          "text": "Ipratropium/albuterol"
        }
      ],
      "text": "A 48-year-old woman with severe chronic obstructive pulmonary disease (COPD) is started on a new once-daily inhaled medication that is a combination of a LABA and a LAMA. What is the name of this medication?",
      "unique_key": "Q3563338",
      "question_audio": null,
      "question_video": null,
      "map_id": 34005434,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (A) Indacaterol/glycopyrrolate. Indacaterol/glycopyrrolate is a combination inhaler that includes a long-acting beta-agonist (LABA), indacaterol, and a long-acting muscarinic antagonist (LAMA), glycopyrrolate. This once-daily inhaled medication is specifically designed for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The combination works synergistically to relax and dilate the airways, improving airflow and reducing COPD symptoms. In the United States, this combination is marketed under the brand name Utibron Neohaler. MAYOCLINIC.ORG Explanation of the Incorrect Options: (B) Salmeterol/fluticasone This combination pairs a LABA (salmeterol) with an inhaled corticosteroid (ICS) (fluticasone). While effective for COPD management, it does not include a LAMA, which is specified in the question. Additionally, this combination is typically administered twice daily, not once daily. (C) Formoterol/budesonide This inhaler combines a LABA (formoterol) with an ICS (budesonide). Similar to option B, it lacks a LAMA component and is usually prescribed for twice-daily use. (D) Ipratropium/albuterol This combination includes a short-acting muscarinic antagonist (SAMA) (ipratropium) and a short-acting beta-agonist (SABA) (albuterol). It is intended for acute symptom relief and is not classified as a long-acting therapy.",
      "correct_choice_id": 246219,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 81238,
      "choices": [
        {
          "id": 246223,
          "text": "Mepolizumab"
        },
        {
          "id": 246224,
          "text": "Benralizumab"
        },
        {
          "id": 246225,
          "text": "Reslizumab"
        },
        {
          "id": 246226,
          "text": "All of the above"
        }
      ],
      "text": "A patient with severe eosinophilic asthma is treated with a recently approved monoclonal antibody that targets IL-5. What is the name of this medication?",
      "unique_key": "Q3366834",
      "question_audio": null,
      "question_video": null,
      "map_id": 34434494,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "Correct Answer (D) All of the above. Mepolizumab, benralizumab, and reslizumab are all monoclonal antibodies approved for the treatment of severe eosinophilic asthma, targeting the interleukin-5 (IL-5) pathway to reduce eosinophil levels and inflammation. A. Mepolizumab: Mepolizumab is a humanized monoclonal antibody that binds directly to IL-5, preventing it from interacting with its receptor on eosinophils. This inhibition reduces the production and survival of eosinophils, thereby decreasing airway inflammation associated with severe eosinophilic asthma. Mepolizumab is administered via subcutaneous injection. EN.WIKIPEDIA.ORG B. Benralizumab: Benralizumab is a humanized monoclonal antibody that targets the IL-5 receptor alpha subunit (IL-5R?) on eosinophils and basophils. By binding to IL-5R?, benralizumab not only blocks IL-5 signaling but also induces antibody-dependent cell-mediated cytotoxicity, leading to rapid and near-complete depletion of eosinophils. This dual action helps control severe eosinophilic asthma. Benralizumab is administered via subcutaneous injection. AACIJOURNAL.BIOMEDCENTRAL.COM C. Reslizumab: Reslizumab is a humanized monoclonal antibody that binds to IL-5, similar to mepolizumab, thereby inhibiting its interaction with the IL-5 receptor on eosinophils. This action reduces eosinophil levels and associated inflammation in severe eosinophilic asthma. Reslizumab is administered via intravenous infusion.",
      "correct_choice_id": 246226,
      "solution_audio": null,
      "solution_video": "",
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [],
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    }
  ]
}